Cellectar Biosciences, Inc. – NASDAQ:CLRB
Cellectar Biosciences stock price today
$4.71
+4.40
+1425.26%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 3 hours
Cellectar Biosciences stock price monthly change
-87.79%
month
Cellectar Biosciences stock price quarterly change
-87.79%
quarter
Cellectar Biosciences stock price yearly change
-88.11%
year
Cellectar Biosciences key metrics
Market Cap | 9.99M |
Enterprise value | N/A |
P/E | -0.36 |
EV/Sales | N/A |
EV/EBITDA | 0.33 |
Price/Sales | N/A |
Price/Book | 0.62 |
PEG ratio | -0.06 |
EPS | -3.08 |
Revenue | N/A |
EBITDA | -42.05M |
Income | -50.98M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCellectar Biosciences stock price history
Cellectar Biosciences stock forecast
Cellectar Biosciences financial statements
| Jun 2023 | 0 | -8.22M | |
|---|---|---|---|
| Sep 2023 | 0 | -13.73M | |
| Dec 2023 | 330.36K | -7.44M | -2254.67% |
| Mar 2024 | 0 | -21.58M |
| Sep 2025 | 5M | -3.72M | -74.44% |
|---|---|---|---|
| Oct 2025 | 5M | -7.33M | -146.73% |
| Dec 2025 | 6M | -2.26M | -37.7% |
| Dec 2025 | 15.9M | -1.46M | -9.23% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 6509165 | 6.97M | 107.17% |
|---|---|---|---|
| Sep 2023 | 21550765 | 34.90M | 161.96% |
| Dec 2023 | 12075580 | 13.43M | 111.23% |
| Mar 2024 | 42908439 | 16.74M | 39.02% |
| Jun 2023 | -7.52M | 0 | 0 |
|---|---|---|---|
| Sep 2023 | -8.06M | -597.28K | 22.49M |
| Dec 2023 | -9.59M | -266.75K | 441.00K |
| Mar 2024 | -13.36M | -21.63K | 43.84M |
Cellectar Biosciences alternative data
| Aug 2023 | 15 |
|---|---|
| Sep 2023 | 15 |
| Oct 2023 | 15 |
| Nov 2023 | 15 |
| Dec 2023 | 15 |
| Jan 2024 | 15 |
| Feb 2024 | 15 |
| Mar 2024 | 15 |
| Apr 2024 | 15 |
| May 2024 | 20 |
| Jun 2024 | 20 |
| Jul 2024 | 20 |
Cellectar Biosciences other data
15.28%
-15.51%
of CLRB is owned by hedge funds
12
-12
1.07M
-803.22K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2020 | 74074 | 0 |
| Mar 2021 | 5100 | 281690 |
| Sep 2021 | 44417 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | SWIRSKY DOUGLAS J director | Common Stock | 25,000 | $1.04 | $26,000 | ||
Purchase | DRISCOLL FREDERICK W director | Common Stock | 19,417 | $1.04 | $20,252 | ||
Sale | NEIS JOHN director | Series A Warrants | 23,232 | N/A | N/A | ||
Sale | NEIS JOHN director | Series A Warrants | 58,640 | $30.4 | $1,782,656 | ||
Sale | NEIS JOHN director | Series A Warrants | 100,515 | N/A | N/A | ||
Sale | NEIS JOHN director | Series A Warrants | 11,200 | N/A | N/A | ||
Sale | NEIS JOHN director | Series A Warrants | 41,155 | $30.4 | $1,251,112 | ||
Purchase | CARUSO JAMES V director, officer.. | Common Stock | 5,100 | $1.7 | $8,660 | ||
Sale | CARUSO JAMES V director, officer.. | Series A Warrants | 46,948 | N/A | N/A | ||
Purchase | CARUSO JAMES V director, officer.. | Common Stock | 37,037 | $1.35 | $50,000 |
| Patent |
|---|
Application Filling date: 10 Apr 2019 Issue date: 3 Jun 2021 |
Application Filling date: 10 Apr 2019 Issue date: 15 Apr 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q4 2017 22 Mar 2018 | Q4 2017 Earnings Call Transcript |
-
What's the price of Cellectar Biosciences stock today?
One share of Cellectar Biosciences stock can currently be purchased for approximately $4.71.
-
When is Cellectar Biosciences's next earnings date?
Unfortunately, Cellectar Biosciences's (CLRB) next earnings date is currently unknown.
-
Does Cellectar Biosciences pay dividends?
No, Cellectar Biosciences does not pay dividends.
-
How much money does Cellectar Biosciences make?
Cellectar Biosciences has a market capitalization of 9.99M.
-
What is Cellectar Biosciences's stock symbol?
Cellectar Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "CLRB".
-
What is Cellectar Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cellectar Biosciences?
Shares of Cellectar Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cellectar Biosciences's key executives?
Cellectar Biosciences's management team includes the following people:
- Mr. James V. Caruso Pres, Chief Executive Officer & Director(age: 66, pay: $807,500)
- Mr. Jarrod Longcor Chief Bus. Officer(age: 52, pay: $491,010)
- Mr. Dov Elefant Vice President & Chief Financial Officer(age: 58, pay: $450,990)
-
How many employees does Cellectar Biosciences have?
As Jul 2024, Cellectar Biosciences employs 20 workers, which is 33% more then previous quarter.
-
When Cellectar Biosciences went public?
Cellectar Biosciences, Inc. is publicly traded company for more then 19 years since IPO on 10 Nov 2005.
-
What is Cellectar Biosciences's official website?
The official website for Cellectar Biosciences is cellectar.com.
-
Where are Cellectar Biosciences's headquarters?
Cellectar Biosciences is headquartered at 100 Campus Drive, Florham Park, NJ.
-
How can i contact Cellectar Biosciences?
Cellectar Biosciences's mailing address is 100 Campus Drive, Florham Park, NJ and company can be reached via phone at +60 84 418 120.
Cellectar Biosciences company profile:
Cellectar Biosciences, Inc.
cellectar.comExchange:
NASDAQ
Full time employees:
20
Industry:
Biotechnology
Sector:
Healthcare
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
100 Campus Drive
Florham Park, NJ 07932
Florham Park, NJ 07932
CIK: 0001279704
ISIN: US15117F8077
CUSIP: 15117F500
